E therapeutics Plc Performance
| ETXPFDelisted Stock | USD 0.13 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and E Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days E therapeutics Plc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, E Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 7 M | |
| Total Cashflows From Investing Activities | -9.9 M |
ETXPF |
E Therapeutics Relative Risk vs. Return Landscape
If you would invest 13.00 in E therapeutics Plc on October 18, 2025 and sell it today you would earn a total of 0.00 from holding E therapeutics Plc or generate 0.0% return on investment over 90 days. E therapeutics Plc is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than ETXPF, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
E Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for E Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as E therapeutics Plc, and traders can use it to determine the average amount a E Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ETXPF |
Based on monthly moving average E Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of E Therapeutics by adding E Therapeutics to a well-diversified portfolio.
E Therapeutics Fundamentals Growth
ETXPF Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of E Therapeutics, and E Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ETXPF Pink Sheet performance.
| Return On Equity | -0.32 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (36.00) % | |||
| Current Valuation | 125.36 M | |||
| Shares Outstanding | 582.16 M | |||
| Price To Book | 4.70 X | |||
| Price To Sales | 506.96 X | |||
| Revenue | 477 K | |||
| EBITDA | (9.29 M) | |||
| Cash And Equivalents | 21.81 M | |||
| Cash Per Share | 0.04 X | |||
| Total Debt | 494 K | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 0.05 X | |||
| Cash Flow From Operations | (7.8 M) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 29.76 M | |||
About E Therapeutics Performance
By analyzing E Therapeutics' fundamental ratios, stakeholders can gain valuable insights into E Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if E Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if E Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
e-Therapeutics plc engages in drug discovery research activities in the United Kingdom. The company was incorporated in 2001 and is based in London, the United Kingdom. E-Therapeutics Plc operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs people.Things to note about E therapeutics Plc performance evaluation
Checking the ongoing alerts about E Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for E therapeutics Plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| E therapeutics Plc is not yet fully synchronised with the market data | |
| E therapeutics Plc has some characteristics of a very speculative penny stock | |
| E therapeutics Plc has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 477 K. Net Loss for the year was (8.07 M) with profit before overhead, payroll, taxes, and interest of 477 K. | |
| E therapeutics Plc has accumulated about 21.81 M in cash with (7.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| Roughly 63.0% of the company shares are held by company insiders |
- Analyzing E Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether E Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining E Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating E Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of E Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of E Therapeutics' pink sheet. These opinions can provide insight into E Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in ETXPF Pink Sheet
If you are still planning to invest in E therapeutics Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the E Therapeutics' history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |